Related Experiment Video

Updated: Aug 18, 2026

The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

Escitalopram and suicidality in adult depression and anxiety

Anders Gersel Pedersen1

  • 1Drug Development, H. Lundbeck A/S, Copenhagen, Denmark. agpe@lundbeck.com

International Clinical Psychopharmacology
|April 7, 2005
PubMed

Insights

Escitalopram did not increase suicidal behavior compared to placebo in major depressive disorder (MDD) and anxiety trials. The drug effectively lowered suicidal thoughts in MDD patients during early treatment.

Area of Science:

  • Psychiatry
  • Clinical Pharmacology
  • Neuroscience

Background:

  • Antidepressant medications are crucial for treating major depressive disorder (MDD) and anxiety disorders.
  • Concerns regarding the potential for antidepressants to increase suicidal behavior, particularly in younger populations, necessitate rigorous investigation.
  • Escitalopram is a widely prescribed selective serotonin reuptake inhibitor (SSRI).

Purpose of the Study:

  • To evaluate the risk of suicidal behavior (fatal suicide, non-fatal self-harm, suicidal thoughts) associated with escitalopram compared to placebo.
  • To assess the efficacy of escitalopram in reducing suicidal ideation in patients with MDD.

Main Methods:

  • Analysis of a comprehensive clinical trial database including placebo-controlled and relapse prevention trials for MDD and anxiety disorders.
  • Systematic review of adverse events specifically related to suicidal behavior.
  • Utilized the Montgomery-Asberg Depression Rating Scale (MADRS) item 10 to assess suicidal thoughts.

Main Results:

  • The incidence of suicidal behavior events was low across all treatment groups.
  • No statistically significant differences in suicidal behavior events were observed between escitalopram and placebo groups.
  • Escitalopram demonstrated superior efficacy in reducing suicidal thoughts compared to placebo within the first 8 weeks of treatment for MDD.

Conclusions:

  • Escitalopram does not appear to provoke suicidal behavior in patients with MDD or anxiety disorders when compared to placebo.
  • Escitalopram is an effective treatment for reducing suicidal ideation in patients with MDD, particularly during the initial weeks of therapy.

Related Concept Videos

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...